Issues and approaches for ensuring effective communication on acceptable daily exposure (ADE) values applied to pharmaceutical cleaning.

This manuscript centers on communication with key stakeholders of the concepts and program goals involved in the application of health-based pharmaceutical cleaning limits. Implementation of health-based cleaning limits, as distinct from other standards such as 1/1000th of the lowest clinical dose, is a concept recently introduced into regulatory domains. While there is a great deal of technical detail in the written framework underpinning the use of Acceptable Daily Exposures (ADEs) in cleaning (for example ISPE, 2010; Sargent et al., 2013), little is available to explain how to practically create a program which meets regulatory needs while also fulfilling good manufacturing practice (GMP) and other expectations. The lack of a harmonized approach for program implementation and communication across stakeholders can ultimately foster inappropriate application of these concepts. Thus, this period in time (2014-2017) could be considered transitional with respect to influencing best practice related to establishing health-based cleaning limits. Suggestions offered in this manuscript are intended to encourage full and accurate communication regarding both scientific and administrative elements of health-based ADE values used in pharmaceutical cleaning practice. This is a large and complex effort that requires: 1) clearly explaining key terms and definitions, 2) identification of stakeholders, 3) assessment of stakeholders' subject matter knowledge, 4) formulation of key messages fit to stakeholder needs, 5) identification of effective and timely means for communication, and 6) allocation of time, energy, and motivation for initiating and carrying through with communications.

[1]  F. Brown,et al.  Quality of biotechnological products : Stability testing of biotechnological/ biological products : International Conference on Harmonisation (ICH) , 1998 .

[2]  M L Dourson,et al.  Regulatory history and experimental support of uncertainty (safety) factors. , 1983, Regulatory toxicology and pharmacology : RTP.

[3]  Patricia A Weideman,et al.  Using default methodologies to derive an acceptable daily exposure (ADE). , 2016, Regulatory toxicology and pharmacology : RTP.

[4]  A G Renwick,et al.  Structure-based thresholds of toxicological concern--guidance for application to substances present at low levels in the diet. , 2005, Toxicology and applied pharmacology.

[5]  D. Barnes,et al.  Reference dose (RfD): description and use in health risk assessments. , 1988, Regulatory toxicology and pharmacology : RTP.

[6]  Reena Sandhu,et al.  A harmonization effort for acceptable daily exposure application to pharmaceutical manufacturing - Operational considerations. , 2016, Regulatory toxicology and pharmacology : RTP.

[7]  Reena Sandhu,et al.  The regulatory framework for preventing cross-contamination of pharmaceutical products: History and considerations for the future. , 2016, Regulatory toxicology and pharmacology : RTP.

[8]  Patricia A Weideman,et al.  Point of departure (PoD) selection for the derivation of acceptable daily exposures (ADEs) for active pharmaceutical ingredients (APIs). , 2016, Regulatory toxicology and pharmacology : RTP.

[9]  P. Anderson,et al.  Human pharmaceuticals in US surface waters: a human health risk assessment. , 2005, Regulatory toxicology and pharmacology : RTP.

[10]  Thomas Pfister,et al.  Guidance on the establishment of acceptable daily exposure limits (ADE) to support Risk-Based Manufacture of Pharmaceutical Products. , 2013, Regulatory toxicology and pharmacology : RTP.

[11]  Janet Gould,et al.  Special endpoint and product specific considerations in pharmaceutical acceptable daily exposure derivation. , 2016, Regulatory toxicology and pharmacology : RTP.

[12]  It Istituto Superiore di Sanit,et al.  Common implementation strategy for the water framework directive (2000/60/EC). Guidance document on euthrophication assessment in the context of European water policies. (Technical report 2009-030; Guidance document 23) , 2009 .

[13]  Patricia A Weideman,et al.  Identifying and assessing highly hazardous drugs within quality risk management programs. , 2016, Regulatory toxicology and pharmacology : RTP.

[14]  Ester Lovsin Barle,et al.  Functional differentiation of cytotoxic cancer drugs and targeted cancer therapeutics. , 2014, Regulatory toxicology and pharmacology : RTP.

[15]  Richard W. Lewis,et al.  Recognition of Adverse and Nonadverse Effects in Toxicity Studies , 2002, Toxicologic pathology.

[16]  R. Kroes Structure-Based Thresholds of Toxicological Concern (TTC): Guidance for Application to Substances Present at Low Levels in the Diet , 2004, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[17]  Jeffery A Engelhardt,et al.  The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s). , 2005, Regulatory toxicology and pharmacology : RTP.

[18]  Joel P Bercu,et al.  Human health risk assessments for three neuropharmaceutical compounds in surface waters. , 2008, Regulatory toxicology and pharmacology : RTP.

[19]  Thomas Pfister,et al.  Toxicokinetic and toxicodynamic considerations when deriving health-based exposure limits for pharmaceuticals. , 2016, Regulatory toxicology and pharmacology : RTP.

[20]  Thomas Pfister,et al.  A harmonization effort for acceptable daily exposure derivation - Considerations for application of adjustment factors. , 2016, Regulatory toxicology and pharmacology : RTP.